A COMPARISON OF THE COMPONENT COMPOSITION OF THE BODY IN PATIENTS WITH LIVER CIRRHOSIS AND HEALTHY INDIVIDUALS FROM THE FIRST AND SECOND PERIODS OF ADULTHOOD

A decreased synthetic liver function, caused by cirrhosis of various etiologies, leads to significant changes in the body component composition. Patients suffering from compensated cirrhosis already have changes in muscular and fat components with an increased risk of developing sarcopenia and sarcopenic obesity. At this stage cirrhosis mostly does not affect the level of the mineral body component, however it does not exclude strict monitoring of this parameter. Inclusion of these parameters in cirrhotic prognostic scales may lead to more profound assessment of the degree of systemic changes due liver injures.
Objective. To evaluate the nature of changes in the body component composition in cirrhotic patients and healthy people of the I and II periods of adulthood.
Material and methods. The study involved 104 patients of Hepatology Department of Sechenov University Clinical Hospital No. 2 with class A cirrhosis and 78 healthy volunteers. The measurement of anthropometric indicators was carried out by the ABC- 01 «MEDASS» device (STC «MEDASS», Russia). The statistical analysis was performed in the STATISTICA 10 program (StatSoft Inc., Tulsa, Oklahoma, USA).
Results. The median index of musculoskeletal mass for volunteers I and II maturity period was 53.9% [50.6-57.2%] vs 51.75% [48.9-54.6%] (p=0,003); fat mass – 19,8% [13,2-26,4%] vs 24.6% [19.2-30%] (p=0,017); mineral mass – 5,66% [5,44-5,87%] vs 5,49% [5,25-5,72%] (p=0,039), respectively. The parameters are typical for patients with class A cirrhosis. Decreased musculoskeletal mass: 45,75% [42,2-49,3%] (p=0,00002); decreased mineral mass: 5.49% [5.25-5.72%] (p=0,081); increased fat mass: 33,5% [27,1-39,9%] (p=0,048) were seen in volunteers of the second maturity period, respectively.
Conclusion. Based on the results, a decrease in muscular, an increase in fat and the preservation in mineral body component were found in class A cirrhosis according to Child-Pugh score. At the same time, in a healthy cohort, there was a decrease in the percentage of muscular component, an increase in fat component and a decrease in mineral component connected with patients’ age.

1. Aniśko B, Siatkowski I, Wójcik M. Body mass composition analysis as a predictor of overweight and obesity in children and adolescents. Front Public Health. 2024 Apr 24;12:1371420. (in Engl) doi: 10.3389/fpubh.2024.1371420.

2. Bazzocchi A, Gazzotti S, Santarpia L, Madeddu C, Petroni ML, Aparisi Gómez MP. Editorial: Importance of body composition analysis in clinical nutrition. Front Nutr. 2023 Jan 12;9:1080636. (in Engl) doi: 10.3389/fnut.2022.1080636.

3. Nishikawa H, Kim SK, Asai A. Body Composition in Chronic Liver Disease. Int J Mol Sci. 2024 Jan 12;25(2):964. (in Engl) doi: 10.3390/ijms25020964.

4. Kalra A, Yetiskul E, Wehrle CJ, Tuma F. Physiology, Liver. 2023 May 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30571059. (in Engl)

5. Premkumar M, Anand AC. Overview of Complications in Cirrhosis. J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1150-1174. (in Engl) doi: 10.1016/j.jceh.2022.04.021.

6. Zharikov YO, Maslennikov RV, Zharikova TS, Gadjiakhmedova AN, Aliyeva AM, Pontes-Silva A, Nikolenko VN. Changes in the component body composition in liver and modern approaches to their assessment. Crimean Journal of Internal Diseases. 2023; (3): 52-57. (In Russ).

7. Ren W, Zheng J, Yang S, Zhong J, Liu X, Liu X, Feng J, Wei T, Yang Y, Tie C, Hong C, Feng B, Huang R. The relationship between imaging-based body composition abnormalities and long-term mortality in patients with liver cirrhosis. Eur J Radiol. 2024; 180:111707. (in Engl) doi: 10.1016/j.ejrad.2024.111707.

8. Sanchez-Tocino ML, Cigarrán S, Ureña P, González-Casaus ML, Mas-Fontao S, Gracia-Iguacel C, Ortíz A, Gonzalez-Parra E. Definition and evolution of the concept of sarcopenia. Nefrologia (Engl Ed). 2024;44(3):323-330. (in Engl) doi: 10.1016/j.nefroe.2023.08.007.

9. Tanase DM, Valasciuc E, Costea CF, Scripcariu DV, Ouatu A, Hurjui LL, Tarniceriu CC, Floria DE, Ciocoiu M, Baroi LG, Floria M. Duality of Branched-Chain Amino Acids in Chronic Cardiovascular Disease: Potential Biomarkers versus Active Pathophysiological Promoters. Nutrients. 2024;16(12):1972. (in Engl) doi: 10.3390/nu16121972.

10. Ebadi M, Bhanji RA, Mazurak VC, Montano-Loza AJ. Sarcopenia in cirrhosis: from pathogenesis to interventions. J Gastroenterol. 2019;54(10):845-859. (in Engl) doi: 10.1007/s00535-019-01605-6.

11. Mangana Del Rio T, Sacleux SC, Vionnet J, Ichaï P, Denys A, Schneider A, Coilly A, Fraga M, Wetzel A, Koerfer J, Chiche JD, Saliba F, Moradpour D, Becce F, Artru F. Body composition and short-term mortality in patients critically ill with acute-on-chronic liver failure. JHEP Rep. 2023;5(8):100758. (in Engl) doi: 10.1016/j.jhepr.2023.100758.

12. Hui Y, Cui B, Wang X, Sun M, Li Y, Yang W. Sarcopenic obesity in liver disease: handling both sides of the penny. Portal Hypertens Cirrhosis. 2022;1(1):42–56. (in Engl) doi:10.1002/poh2.10

13. Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact. Int J Mol Sci. 2021;22(4):1917. (in Engl) doi: 10.3390/ijms22041917.

14. Musio A, Perazza F, Leoni L, Stefanini B, Dajti E, Menozzi R, Petroni ML, Colecchia A, Ravaioli F. Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease. Int J Mol Sci. 2023;24(8):7517. (in Engl) doi: 10.3390/ijms24087517

15. Polito A, Barnaba L, Ciarapica D, Azzini E. Osteosarcopenia: A Narrative Review on Clinical Studies. Int J Mol Sci. 2022;23(10):5591. (in Engl) doi: 10.3390/ijms23105591

16. Saeki C, Kanai T, Ueda K, Nakano M, Oikawa T, Torisu Y, Saruta M, Tsubota A. Osteosarcopenia predicts poor survival in patients with cirrhosis: a retrospective study. BMC Gastroenterol. 2023;23(1):196. (in Engl) doi: 10.1186/s12876-023-02835-y.